lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
A drop in progesterone levels is possibly one step in the onset of labor. In addition, progesterone inhibits lactation during pregnancy. The fall in progesterone levels following delivery is one of the triggers for milk production. The fetus metabolizes placental progesterone in the production of adrenal steroids.
=== Cultural and other influences === In ancient Egypt, depilation was commonly practiced, with pumice and razors used to shave. In both Ancient Greece and Ancient Rome, the removal of body and pubic hair may have been practiced among both men and women. It is represented in some artistic depictions of male and female nudity, examples of which may be seen in red figure pottery and sculptures like the Kouros of Ancient Greece in which both men and women were depicted without body or pubic hair. Emperor Augustus was said, by Suetonius, to have applied "hot nutshells" on his legs as a form of depilation. In the clothes free movement, the term "smoothie" refers to an individual who has removed their body hair. In the past, such practices were frowned upon and in some cases, forbidden: violators could face exclusion from the club. Enthusiasts grouped together and formed societies of their own that catered to that fashion, and smoothies became a major percentage at some nudist venues. The first Smoothie club (TSC) was founded by a British couple in 1991. A Dutch branch was founded in 1993 in order to give the idea of a hairless body greater publicity in the Netherlands. Being a Smoothie is described by its supporters as exceptionally comfortable and liberating. The Smoothy-Club is also a branch of the World of the Nudest Nudist (WNN) and organizes nudist ship cruises and regular nudist events.
Einstein Bros. Bagels is an American chain of bagel cafes. In the 1990s, the company bought out several retail bagel chains from regions around the US which lacked bagel traditions. After filing for bankruptcy in 2000, the company was bought out by New World Coffee. It became part of Panera Brands in August 2021.
Dosage forms (also called unit doses) are pharmaceutical drug products presented in a specific form for use. They contain a mixture of active ingredients and inactive components (excipients), configured in a particular way (such as a capsule shell) and apportioned into a specific dose. For example, two products may both be amoxicillin, but one may come in 500 mg capsules, while another may be in 250 mg chewable tablets. The term unit dose can also refer to non-reusable packaging, particularly when each drug product is individually packaged. However, the FDA differentiates this by referring to it as unit-dose "packaging" or "dispensing". Depending on the context, multi(ple) unit dose may refer to multiple distinct drug products packaged together or a single product containing multiple drugs and/or doses.
=== Data breach === According to an October 2020 report, for months, the company stored hundreds of massive spreadsheets containing sensitive patient data in an Amazon Web Services storage bucket without a password. TechCrunch was the first news source to report the data breach.
Sources: en.wikipedia.org
This being the reason for seeing mass decay between 660 °C and 710 °C. Differences in differential thermogram (DTG) peaks for TLW were compared to TSW. TLW had four distinctive peaks at 87, 195, 265, and 306 °C whereas TSW had two major drop offs at 200 and 306 °C with one spike in between. The four peaks indicated that TLW contains more diverse types of additives than TSW. The residual mass percentage between TLW and TSW was further compared, where the residual mass in TSW was less than that of TLW for both CO2 and N2 environments concluding that TSW has higher quantities of additives than TLW.
== Legacy == His career in the industry is acknowledged through the "Frank Vale Award" which is presented annually at the Refrigerated Warehouse and Transport Association of Australia (RWTA) Conference and Exhibition to an outstanding young achiever.
== Early life and education == King was born in 1934 in an army family. Since childhood, King enjoyed hiking and camping. He graduated from Episcopal High School in Alexandria, Virginia. He received a B.E. in chemical engineering from Yale University in 1956. He then entered Massachusetts Institute of Technology, where he received S.M. in chemical engineering in 1958 and Sc.D. in chemical engineering in 1960, under the supervision of J. Edward Vivian.
=== Etymology === The word tulip, first mentioned in western Europe in or around 1554 and seemingly derived from the "Turkish Letters" of diplomat Ogier Ghiselin de Busbecq, first appeared in English as tulipa or tulipant, entering the language by way of French: tulipe and its obsolete form tulipan or by way of Modern Latin tulipa, from Ottoman Turkish tülbend ("muslin" or "gauze"), and may be ultimately derived from the Persian: دُلبند dulband ("Turban"), this name being applied because of a perceived resemblance of the shape of a tulip flower to that of a turban. This may have been due to a translation error in early times when it was fashionable in the Ottoman Empire to wear tulips on turbans. The translator possibly confused the flower for the turban.
Sources: en.wikipedia.org
== External links == Procter and Gamble web page for Intrinsa. Information on Intrinsa and User Forum Patch 'to boost female sex drive' FDA Looks at P&G's Sex-Drive Drug Women's sexual health deserves equal attention
Following his 2011 announcement to end the feud, Ja Rule and Irv Gotti would further detail their internal conflicts during a 2013 interview with HOT 97's Angie Martinez. The two acknowledged their feud with 50 Cent had not only taken a toll on Ja Rule's prominence, but in connection to the federal indictment, damaged Murder, Inc., as a music label. In describing to Martinez their immediate reaction on hearing 50 Cent's single, "In Da Club", on the radio in 2003, describing it as "so dope" and indicating that they had a problem with its success. The two also disclosed that they had found themselves blackballed from various award shows and other events in which 50 Cent was to perform due to safety concerns. Notwithstanding seeing 50 Cent as a hustler, they showed respect at his entrepreneurial mentality, indicating their desires to end any further tensions at the time.
A definite diagnosis of transfusion-transmitted bacterial infection includes the identification of a positive culture in the recipient (without an alternative diagnosis) as well as the identification of the same organism in the donor blood. Since the advent of HIV testing of donor blood in the mid/later 1980s, ex. 1985's ELISA, the transmission of HIV during transfusion has dropped dramatically. Prior testing of donor blood only included testing for antibodies to HIV. However, because of latent infection (the "window period" in which an individual is infectious, but has not had time to develop antibodies) many cases of HIV seropositive blood were missed. The development of a nucleic acid test for the HIV-1 RNA has dramatically lowered the rate of donor blood seropositivity to about 1 in 3 million units. As transmittance of HIV does not necessarily mean HIV infection, the latter could still occur at an even lower rate. The transmission of hepatitis C via transfusion currently stands at a rate of about 1 in 2 million units. As with HIV, this low rate has been attributed to the ability to screen for both antibodies as well as viral RNA nucleic acid testing in donor blood. Other rare transmissible infections include hepatitis B, syphilis, Chagas disease, cytomegalovirus infections (in immunocompromised recipients), HTLV, and Babesia.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.